No down-side to starting durvalumab immediately after chemoradiation for unresectable stage III non-small cell lung cancer-some answers but more questions. Editorial Article uri icon

Overview

publication date

  • February 27, 2025

Identity

PubMed Central ID

  • PMC11898364

Scopus Document Identifier

  • 85219521729

Digital Object Identifier (DOI)

  • 10.21037/jtd-24-1858

PubMed ID

  • 40083527

Additional Document Info

volume

  • 17

issue

  • 2